4536 — Santen Pharmaceutical Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapSuper Stock

Annual cashflow statement for Santen Pharmaceutical Co, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	21,714	6,645	27,189	-14,983	26,703
Depreciation
Non-Cash Items	14,368	46,010	8,253	47,577	15,743
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-12,708	-30,615	-6,454	-12,696	12,025
Change in Accounts Receivable
Change in Inventories
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	39,947	38,808	46,043	37,147	72,649
Capital Expenditures	-9,228	-23,804	-35,841	-24,588	-10,687
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	4,053	-29,551	672	-2,189	4,542
Acquisition of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Sale of Intangible Assets
Other Investing Cash Flow
Cash from Investing Activities	-5,175	-53,355	-35,169	-26,777	-6,145
Financing Cash Flow Items	-446	148	147	445	217
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-12,729	-16,685	5,557	-37,220	-34,031
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	20,633	-28,542	20,125	-25,111	36,679